Precision Medicine Market Size, Share, Trends | Opportunities, Demands and Growth Revenue by 2026 | Brandessence Market Research Report

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (Heraldkeepers) —
The Precision Medicine Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

Precision Medicine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment; technological innovation and advancement , as well as growth of personal healthcare devices are major key factor which drives the Global Precision Medicine Market.

Get Sample Copy of This Premium Report

**The sample pages of this report is immediately accessible on-demand.**

Top Precision Medicine companies:

key strategies followed by the top players operating in the precision medicine market are,

  • Abbott Laboratories
  • GE Healthcare
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Pfizer
  • Laboratories Corporation of America Holdings
  • Danaher Corporation
  • Biocrates Life Sciences AG
  • Nanostring Technologies
  • Intomics
  • Ferrer Incode
  • Eagle Genomics Ltd

Scope of Market Reports –

Precision medicine is often called as Personalized Medicine. It is used to describe how genetic information about a person’s disease is being used to diagnose or treat their disease. Precision Medicine refers to the modification of medical treatment to the individual characteristics of each patient. It does not exactly mean the manufacturing of drugs or medical devices that are unique to a patient, but the ability to categorize individuals into sub-populations that diverge in their susceptibility to a particular disease. Preventive or therapeutic interventions can then be focused on those who will benefit, sparing cost and side effects for those who will not. The main aim of government regulations is to make Precision Medicines more accepted and it is focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases.

The key objective of Cancergenomics is to improve personalized medicine through the DNA sequencing and analysis of patient tumors cells to find out new genetic mutation associated with specific cancers.

Genetic information has helped to increase the development and use of the newest cancer treatments like Chemotherapy, Radiation Therapy, Targeted Therapy and Precision Medicines. For example, the drug Imatinib was modified to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenousleukemia. Another example is the breast cancer drug Trastuzumab which works only for women whose tumors have a particular genetic profile calledHuman Epidermal Growth Factor Receptor 2(HER-2 positive). It is also found that lung cancer patients whose tumors are positive forEstimated Glomerular Filtration Rate (EGFR)mutations will respond to the drugs Gefitinib and Erlotinib which target this mutation. Conversely, colon cancer patients whose tumors have a mutation in a gene called KRAS (K-RAS) derive less benefit from the drugs Cetuximab and Panitumumab. The genomic information made by The Cancer Genome Atlas (TCGA) will boostthe research to develop similar treatment strategies for

Read More

John Rullo: NH demands cultural competence in medicine | Op-eds

“PRADER-WILLI SYNDROME, it’s rare, about one in 25,000 births in the U.S.,” sighed the fresh-faced resident at Massachusetts General Hospital. It was spring of 1997 and my mother was sitting in a cold office cradling my older brother as the white coat in front of her eyed them both as if they were under a microscope. “Just out of curiosity, did you ever consider aborting?”

William was two weeks old. “I think it’s a little late, doc,” my mom thought to herself. This is a quintessential example of parents — mostly mothers — having discouraging or even harmful conversations with health care providers.

Over two decades later and the health care community is still quite concerned with people with varying abilities. So concerned in fact that doctors’ and nurses’ continue to treat people with disabilities as victims of adverse health outcomes and not as members of a unique, diverse and complex population. Members of this community have waited for equity in health care for decades and they continue to wait. Today, in light of the pandemic caused by the novel coronavirus (COVID-19), it is the perfect opportunity to stop waiting.

Hundreds of industries, jobs, technologies and opportunities have changed and adapted in response to COVID-19. I imagine that this change will be lasting and that the lessons learned from this crisis will be foundational to sectors like health care for the rest of our lives. Telehealth and universal access to physicians has blossomed in just the last few months, and I am not simply referring to people such as myself who are inconvenienced by shuttered offices, but those who require — and have for a while — the accessibility rendered by these new technologies.

COVID-19 has elucidated two issues: it exacerbates the needs of a vulnerable population and it forces us to creatively leverage circumstance into possibility. ABLE NH and the Disability Diagnosis Dialogues (DDD) Task Force are on the vanguard of that possibility.

The mission of DDD is to reframe how the diagnosis of a disability is delivered in a positive and empowering way so that parents might be informed and prepared. The workshops are about discussions, the discussions are about dignity.

The workshops and discussions that DDD facilitates act as reminders that every person’s life is one of value and meaning. Physicians, as the first point of contact for many parents, must be sensitive to how their methods and training affect that message. I am neither interested in nor qualified to tell doctors how to do their jobs, but I am concerned with who is the keeper of information that can be life-changing for families, and how that information is delivered. Our workshops aim to improve the work of health care providers, ease the anxiety of new parents, and augment the communication of knowledge and resources.

This pressing opportunity transcends the call to physicians and advocates; mothers, families, and children must take charge of one of the most critical times of their lives, and refuse the gatekeeping, esoteric,

Read More

Nuclear Medicine Radioisotopes Market Share, Size 2020 Opportunities, Demands, Size, Share, Trends, Industry Sales Area and Its Competitors by 2025

The MarketWatch News Department was not involved in the creation of this content.

Nov 04, 2020 (The Expresswire) —
Global Nuclear Medicine Radioisotopes Market (2020-2025) status and position of worldwide and key regions, with perspectives of manufacturers, regions, product types and end industries. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. this report analyses the topmost companies in worldwide and main regions, and splits the Nuclear Medicine Radioisotopes market by product type and applications/end industries. Global Nuclear Medicine Radioisotopes Market Report 2020 provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Get a sample PDF of the report at–

Nuclear Medicine Radioisotopes Market 2020 Research report contains a qualified and in-depth examination of Nuclear Medicine Radioisotopes Market. At first, the report provides the current business situation along with a valid assessment of the Nuclear Medicine Radioisotopes Industry. This report is partitioned based on driving Nuclear Medicine Radioisotopes players, application and regions. The progressing Nuclear Medicine Radioisotopes economic situations are additionally discovered in the report.

Based on the Nuclear Medicine Radioisotopes market development status, competitive landscape and development model in different regions of the world, this report is dedicated to providing niche markets, potential risks and comprehensive competitive strategy analysis in different fields. From the competitive advantages of different types of products and services, the development opportunities and consumption characteristics and structure analysis of the downstream application fields are all analyzed in detail. To Boost Growth during the epidemic era, this report analyzes in detail for the potential risks and opportunities which can be focused on.

Global Nuclear Medicine Radioisotopes Market Report 2020 provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

To Understand How COVID-19 Impact is Covered in This Report. Get Sample copy of the report at –

List Of TOP KEY PLAYERS in Nuclear Medicine Radioisotopes Market Report are –

● Ge Healthcare ● Medx Inc ● Bracco S.p.A ● Segami Corporation ● Naviscan Inc ● NTP Radioisotopes SOC Ltd ● Agfa-Gevaert N.V. ● Digirad Corporation ● Nordion (Canada) Inc. ● Gamma Medica Inc ● Curium ● Positron Corporation ● Hologic Inc. ● Siemens Healthcare ● Cardiarc Ltd ● CMR Naviscan (Gamma Medica Inc.) ● Cardinal Health Inc.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

With tables and figures helping analyze worldwide Global Nuclear Medicine Radioisotopes Market Forecast provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Enquire before purchasing this report-

on the basis of types, the Nuclear Medicine Radioisotopes market from 2015 to 2025 is primarily split into

● Rubidium-82 (Rb-82) ● Actinium-225 (Ac-225) ● Radium-223 (Ra-223) and Alpharadin ● Technetium-99m (Tc-99m) ● Thallium-201 (Tl-201) ● Iodine (I-123) ● Fluorine-18 ● Iodine-131 (I-131) ● Lutetium-177 (Lu-177) ● Others

on the basis of applications, the Nuclear

Read More